No Data
No Data
Sichuan Kelun Pharmaceutical's (SZSE:002422) 24% CAGR Outpaced the Company's Earnings Growth Over the Same Three-year Period
We Think Sichuan Kelun Pharmaceutical (SZSE:002422) Can Manage Its Debt With Ease
Sichuan Kelun Pharmaceutical Gets Drug Registration Approval for Dydrogesterone Tablets
Sichuan Kelun Pharmaceutical (002422.SZ) has obtained pharmaceutical registration approval for its Diqutunone tablets.
Sichuan Kelun Pharmaceutical (002422.SZ) announced on September 18th that the company's chemical drug "Diqukun Pill" has recently obtained the drug registration approval from the National Medical Products Administration. It is reported that Diqukun Pill, developed by Abbott Laboratories, has been approved for sale in more than 100 countries, and is used to treat related diseases caused by endogenous progesterone deficiency, such as dysmenorrhea, endometriosis, threatened miscarriage or habitual miscarriage caused by progesterone deficiency, and luteal support in assisted reproduction technology. Diqukun is a synthetic progesterone that has the closest structure and function to natural progesterone. Compared with natural progesterone progesterone, its
Sichuan Kelun Pharmaceutical to Present Results of Cancer Drug Studies at Barcelona Oncology Meet
Sichuan Kelun Pharmaceutical (002422.SZ): Its subsidiary's core product sac-TMT was announced the research results at the European Oncology Congress in 2024.
Gelonghui, September 9th: Sichuan Kelun Pharmaceutical (002422.SZ) announced that the company recently learned that at the European Society for Medical Oncology (ESMO) conference in Barcelona, Spain, from September 13th to 17th, 2024, the company's controlling subsidiary Sichuan Kelun Botai Biomedical (referred to as "Kelun Botai") will announce the following research results: 1. During the local time on September 15, 2024, from 14:55 to 15:00 in the small oral presentation session (report number: 716MO), the announcement of the resistance
No Data
No Data